Kelvin Alexander Moses, MD, PhD, associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer (mHSPC).

Combination strategies are currently under investigation, says Moses. Additionally, checkpoint inhibitors are being explored in men with specific alterations, such as 

 State of the Science Summit™ on Genitourinary Malignancies, Kirk A. Keegan, MD, MPH, spoke about advanced diagnostic imaging modalities, says Moses. Advanced imaging may allow for earlier detection and intervention of metastatic prostate cancer. However, further research is needed to determine if there is a comparable survival advantage with earlier treatment exposure as with current approved agents, concludes Moses.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Vanderbilt-Ingram Cancer Center

Cancer Centers

Partner

Kelvin Alexander Moses, MD, PhD, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer.

Dr. Moses On Ongoing Trials in mHSPC